Medexus Pharmaceuticals (MDP) Bloom Burton & Co. Healthcare Investor Conference 2025 summary

Business overview and strategy

• Operates in the U.S. and Canada with $113 million in annual revenue and 15 products across both markets.

• Focuses on hematology, oncology, allergy, dermatology, and autoimmune diseases, with commercial and pipeline assets in each.

• Growth strategy centers on licensing and M&A, not traditional R&D, minimizing development risk.

• Management owns about 10%, aligning interests with shareholders.

• Commercial infrastructure is leveraged for new products, supporting margin expansion and scalability.

Key product and market developments

• Treosulfan (Grafapex) is a major growth catalyst, recently approved in the U.S., expected to exceed $100 million in annual revenue.

• Treosulfan offers an 80% gross margin, higher than the current 55%-60% portfolio average.

• Early U.S. uptake is strong, with rapid reimbursement and prior authorizations at key institutions.

• Canadian sales of Treosulfan are accelerating with new government reimbursement.

• Clinical studies show significant improvements in survival and reduced toxicity for Treosulfan.

Financial performance and outlook

• Quarterly revenue is steady, with $30 million in the last reported quarter and $5.8 million EBITDA, including $2 million in Treosulfan launch costs.

• Free cash flow closely tracks EBITDA, historically around $20 million annually, with temporary dips during product launches.

• Net debt is now $10–$15 million after a recent $20 million capital raise, with 32 million shares outstanding.

• Ongoing Treosulfan marketing and infrastructure costs are $3–$4 million per quarter, expected to remain flat over the next seven years.

• Margin appreciation is anticipated as Treosulfan's contribution grows.